LRIG1 and squamous epithelial uterine cervical cancer: Correlation to prognosis, other tumor markers, sex steroid hormones, and smoking

International Journal of Gynecological Cancer

Volumn 18, Issue 2, 2008, Pages 312-317

  Lindstrom A K ^a,b   Ekman, K ^c   Stendahl, U ^a   Tot, T ^c   Henriksson, R ^a   Hedman, H ^a   Hellberg, D ^d,e  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b Ventrum Clinic   (Sweden)

^c FALUN HOSPITAL   (Sweden)

^d Center for Clinical Research   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

Author keywords

Cervix cancer; Hormones; LRIG; Prognosis; Smoking

Indexed keywords

ESTRADIOL; PROGESTERONE; PROTEIN LRIG1; SEX HORMONE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY DIAGNOSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SMOKING; SQUAMOUS CELL CARCINOMA; UTERINE CERVIX CANCER;

EID: 40549088610     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.01021.x     Document Type: Article

References (32)

1. 1 Suzuki Y, Sato N, Tohyama M, Wanaka A, Takagi T. cDNA cloning of a novel membrane glycoprotein that is expressed specifically in glial cells in the mouse brain. J Biolumin Chemilumin 1996 ; 271: 22522–7.
2. 2 Nilsson J, Vallbo C, Guo D et al. Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 2001 ; 284: 1155–61.
3. 3 Ghiglione C, Carraway KL III, Amundadottir LT, Boswell RE, Perrimon N, Duffy JB. The transmembrane molecule kekkon 1 acts in a negative feedback loop to negatively regulate the activity of the Drosophila EGF receptor during oogenesis. Cell 1999 ; 96: 847–56.
4. 4 Nilsson J, Starefeldt A, Henriksson R, Hedman H. LRIG1 protein in human cells and tissues. Cell Tissue Res 2003 ; 312: 65–71.
5. 5 Guo D, Holmlund C, Henriksson R, Hedman H. The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and homolog in Ascidiacea. Genomics 2004 ; 84: 157–65.
6. 6 Hedman H, Nilsson J, Guo D, Henriksson R. Is LRIG1 a tumour suppressor gene at chromosome 3p14.3? Acta Oncol 2002 ; 41: 352–4.
7. 7 Thomasson M, Hedman H, Guo D, Ljungberg B, Henriksson R. LRIG1 and epidermal growth factor receptor in renal cell carcinoma: a quantitative RT‐PCR and immunohistochemical analysis. Br J Cancer 2003 ; 89: 1285–9.
8. 8 Gur G, Rubin C, Katz M et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 2004 ; 23: 3270–81.
9. 9 Laederich MB, Funes‐Duran M, Yen L et al. The leucine‐rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 2004 ; 279: 47050–6.
10. 10 Ljuslinder I, Malmer B, Golovleva I et al. Increased copy number of 3p14 in breast cancer. Breast Cancer Res 2005 ; 7: 719–27.
11. 11 Holmlund C, Nilsson J, Guo D et al. Characterization and tissue‐specific expression of human LRIG2. Gene 2004 ; 332: 35–43.
12. 12 Benedet JL, Bender H, Jones H III, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynaecological cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000 ; 70: 209–62.
13. 13 Tot T. Adenocarcinomas metastatic to the liver. The value of cytokeratins 20 and 7 in the search for unknown primary tumors. Cancer 1999 ; 85: 171–7.
14. 14 Serra R, Crowley MR. Mouse models of transforming growth factor beta impact in breast development and cancer. Endocrine-related cancer 2005 ; 12: 749–60.
15. 15 Ngan HY, Cheung AN, Liu SS, Ng TY, Wong LC. Abnormal expression of pan‐ras, c‐myc and tp53 in squamous cell carcinoma of cervix: correlation with HPV and prognosis. Oncol Rep 2001 ; 8: 557–61.
16. 16 Horn L‐C, Fischer U, Hänel C, Kuhn H, Raptis G, Bilek K. p53 in surgically treated and pathologically staged cervical cancer: correlation with local tumor progression, but not with lymphatic spread. Pathol Res Pract 2001 ; 197: 605–9.
17. 17 Skomedal H, Kristensen GB, Lie AK, Holm R. Aberrant expression of the cell cycle associated proteins TP53, MDM2, p21. p27, Cyclin D1, RB, and EGFR in cervical carcinomas. Gynecol Oncol 1999 ; 73: 223–8.
18. 18 Suzuki Y, Miura H, Tanemura A et al. Targeted disruption of LIG‐1 gene results in psoriasiform epidermal hyperplasia. FEBS Letters 2002 ; 521: 67–71.
19. 19 Tanemura A, Nagasawa T, Inui S, Itami S. LRIG‐1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 2005 ; 31: 423–30.
20. 20 Kim YT, Zhao M. Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J 2005 ; 46: 597–613.
21. 21 Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ. CD44 family and gynaecological cancer. In Vivo 2003 ; 17: 633–40.
22. 22 Linehan DC, Goedegebuure PS. CD25+ CD4+ regulatory T‐cells in cancer. Immunol Res 2005 ; 32: 155–68.
23. 23 Foty RA, Steinberg MS. Cadherin‐mediated cell‐cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 2004 ; 48: 397–409.
24. 24 Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005 ; 23: 1011–27.
25. 25 Wade M, Wahl GM. C‐Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol 2006 ; 302: 169–203.
26. 26 Telliez A, Furman C, Pommery N, Henichart JP. Mechanisms leading to COX‐2 expression and COX‐2 induced tumorigenesis: topical therapeutic strategies targeting COX‐2 expression and activity. Medicin Chem–Anticancer agents 2006 ; 6: 187–208.
27. 27 Deligeoroglou E, Michailidis E, Creatsas G. Oral contraceptives and reproductive system cancer. Ann NY Acad Sci 2003 ; 997: 199–208.
28. 28 Yuan F, Auborn K, James C. Altered growth and viral gene expression in human papillomavirus type 16‐containing cancer cell lines treated with progesterone. Cancer Invest 1999 ; 17: 19–29.
29. 29 Lindstrom A, Backstrom T, Hellberg D, Tribukait B, Strang P, Stendahl U. Correlations between serum progesterone and smoking, and the growth fraction of cervical squamous cell carcinoma. Anticancer Res 2000 ; 20: 3637–40.
30. 30 Hellberg D, Lindström AK, Stendahl U. Correlation between serum estradiol/progesterone ratio and survival length in invasive squamous cell cervical cancer. Anticancer Res 2005 ; 25: 611–6.
31. 31 Hellberg D, Valentin J, Nilsson S. Smoking as risk factor in cervical neoplasia. Lancet 1983 ; 2: 1497.
32. 32 Hellberg D, Nilsson S, Haley NJ, Hoffman D, Wynder E. Smoking and cervical intraepithelial neoplasia: nicotine and cotinine in serum and cervical mucus in smokers and nonsmokers. Am J Obstet Gynecol 1988 ; 158: 910–3.